---
title: "Allopregnanolone and the Link Between Prenatal Psychosocial Distress and Birth Length: Findings fr"
id: "medrxiv-2-evaluating-allopregnanolone-as-a-potential-mediator-of-prenatal-psychosocial"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-evaluating-allopregnanolone-as-a-potential-mediator-of-prenatal-psychosocial"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1?rss=1"
published_at: "2026-07-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Allopregnanolone and the Link Between Prenatal Psychosocial Distress and Birth Length: Findings fr
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-evaluating-allopregnanolone-as-a-potential-mediator-of-prenatal-psychosocial
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1?rss=1)
- **Published At:** 2026-07-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluated whether maternal **allopregnanolone (ALLO)** concentrations or the **ALLO-to-progesterone ratio** mediate associations between prenatal psychosocial distress and birth outcomes in the Healthy Start cohort. - The sample included 237 pregnant participants, enriched for psychosocial distress (57 high-distress, 180 low-distress) with psychosocial distress measured using the Edinburgh Perinatal Depression Scale (EPDS) and EPDS-3A. - Maternal serum ALLO and related steroid hormones were measured at approximately 17 and 27 weeks' gestation (range 10–34 weeks) using a validated HPLC-MS/MS assay. ALLO and the ALLO-to-progesterone ratio were natural log-transformed for analysis. - The primary outcome was gestational age at birth. Secondary outcomes were birthweight-for-gestational-age z-score (BW/GA), percent fat mass (%FM), and birth length-for-gestational-age z-score (BL/GA). - Regression-based mediation analyses compared total and direct effects of prenatal psychosocial distress after adjustment for each proposed mediator. - Prenatal psychosocial distress was associated only with shorter **birth length-for-gestational-age (BL/GA)** (β = -0.49; 95% CI: -0.84, -0.14) among the birth outcomes assessed. - Adjustment for ALLO measured at ~27 weeks minimally attenuated the distress–BL/GA association (β = -0.46; 95% CI: -0.81, -0.10) corresponding to 6.1% attenuation. - Adjustment for the **ALLO-to-progesterone ratio** at ~27 weeks resulted in greater attenuation (β = -0.38; 95% CI: -0.74, -0.03), corresponding to 20.8% attenuation, suggesting partial mediation. - The authors conclude maternal prenatal distress was linked to shorter birth length and that neurosteroid metabolism, reflected by the **ALLO-to-progesterone ratio**, may partially mediate this relationship. - The report notes the need for future mechanistic studies to confirm these findings. Details on other potential confounders, full model covariates, and additional subgroup analyses were not reported in the abstract and would require consulting the full preprint.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=DbyKEUlN4Jf7uE6B3.O24SX1C0ASlNfik5FZHU7OwQc-1785282903.3997998-1.2.1.1-ShM8DAvjGYuF4WbGQzI84v0iMXOHFfqFOe8aKswhi_U) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Evaluating Allopregnanolone as a Potential Mediator of Prenatal Psychosocial Distress and Birth Outcomes in the Healthy Start Cohort [ View ORCID Profile](http://orcid.org/0000-0001-9860-2939)Gabriella B Mayne, K Joseph Hurt, Sara Yeatman, Jost Klawitter, David P Tracer, Uwe Christians, Dana Dabelea, Wei Perng doi: https://doi.org/10.64898/2026.07.26.26358958 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Gabriella B Mayne 1 University of Colorado, Denver; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gabriella%2BB%2BMayne%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mayne%20GB&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGabriella%2BB%2BMayne%2B) * [ORCID record for Gabriella B Mayne](http://orcid.org/0000-0001-9860-2939 "Open in new tab") * For correspondence: gabriella.2.mayne@ucdenver.edu K Joseph Hurt 2 University of Colorado, Anschutz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=K%2BJoseph%2BHurt%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hurt%20KJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AK%2BJoseph%2BHurt%2B) Sara Yeatman 1 University of Colorado, Denver; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sara%2BYeatman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yeatman%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASara%2BYeatman%2B) Jost Klawitter 2 University of Colorado, Anschutz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jost%2BKlawitter%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Klawitter%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJost%2BKlawitter%2B) David P Tracer 1 University of Colorado, Denver; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David%2BP%2BTracer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tracer%20DP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid%2BP%2BTracer%2B) Uwe Christians 2 University of Colorado, Anschutz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Uwe%2BChristians%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Christians%20U&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AUwe%2BChristians%2B) Dana Dabelea 2 University of Colorado, Anschutz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dana%2BDabelea%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dabelea%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADana%2BDabelea%2B) Wei Perng 2 University of Colorado, Anschutz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wei%2BPerng%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Perng%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWei%2BPerng%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1266776/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1266776/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1266776/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1266776/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1266776/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1266776/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Prenatal psychosocial distress is a risk factor for adverse birth outcomes such as preterm birth, but the biological pathways remain incompletely understood. Allopregnanolone (ALLO), a stress-responsive, progesterone-derived neuroactive steroid, may contribute to pregnancy maintenance by inhibiting uterine activation and modulating inflammatory and neuroendocrine pathways involved in parturition. Few human studies have examined ALLO during pregnancy in relation to birth timing and related outcomes, and no study to our knowledge has examined the entire pathway of prenatal psychosocial distress, ALLO, and birth outcomes. Here, we evaluated whether maternal ALLO concentrations and the ALLO-to-progesterone ratio mediate associations between prenatal psychosocial distress and birth outcomes. Methods: This study included 237 pregnant participants from the Healthy Start Cohort, enriched for psychosocial distress (n=57 high-distress; n=180 low-distress) assessed using the Edinburgh Perinatal Depression Scale (EPDS) and EPDS-3A anxiety subscale. We measured maternal serum ALLO and related steroid hormones at approximately 17 and 27 weeks gestation (range: 10-34 weeks) using a validated HPLC-MS/MS assay and evaluated natural log (ln)-transformed ALLO and the ALLO-to-progesterone ratio as potential mediators. The primary outcome was gestational age at birth; secondary outcomes included birthweight-for-gestational-age z-score (BW/GA), percent fat mass (%FM), and birth length-for-gestational-age z-score (BL/GA). We conducted regression-based mediation analyses by comparing the total and direct effects of prenatal psychosocial distress after adjustment for each proposed mediator. Results: Participants had a mean +- SD age of 29+-6 years; 38% were nulliparous, and 60% identified as non-Hispanic White. Of the birth outcomes assessed, prenatal psychosocial distress was only associated with BL/GA (β = -0.49; 95% CI: -0.84, -0.14). Adjustment for ALLO at ~27 weeks as a mediator minimally attenuated the association between prenatal distress and BL/GA (β = -0.46; 95% CI: -0.81, -0.10, 6.1% attenuation), whereas adjustment for the ALLO-to-progesterone ratio resulted in 20.8% attenuation (β = -0.38; 95% CI: -0.74, -0.03). Conclusions: Maternal prenatal distress was associated with shorter birth length. The ALLO-to-progesterone ratio, but not ALLO itself, may partially mediate this relationship. These findings support neurosteroid metabolism as a biological pathway linking prenatal distress to fetal length accrual. Future mechanistic studies are needed to confirm these findings. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All participants provided written informed consent, and the Colorado Multiple Institutional Review Board approved the parent study (Healthy Start) and this secondary analysis (COMIRB #09-0563 and #24-0224). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability De-identified participant data and analytic code supporting the findings of this study are available from the corresponding author upon reasonable request and with approval from the Healthy Start Study and the Colorado Multiple Institutional Review Board. ## Funder Information Declared National Institute of Diabetes and Digestive and Kidney Diseases, R01 DK076648 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.07.27.26359007v1 "Can non-routine data collection help decision-making for gambiense sleeping sickness? Using active adaptive management to assess the potential of vector control")[Next ](https://www.medrxiv.org/content/10.64898/2026.07.27.26359055v1 "A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance") Posted July 28, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/07/28/2026.07.26.26358958.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.07.26.26358958v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/07/28/2026.07.26.26358958.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Evaluating Allopregnanolone as a Potential Mediator of Prenatal Psychosocial Distress and Birth Outcomes in the Healthy Start Cohort Gabriella B Mayne, K Joseph Hurt, Sara Yeatman, Jost Klawitter, David P Tracer, Uwe Christians, Dana Dabelea, Wei Perng medRxiv 2026.07.26.26358958; doi: https://doi.org/10.64898/2026.07.26.26358958 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.26.26358958v1%26text%3DEvaluating%2520Allopregnanolone%2520as%2520a%2520Potential%2520Mediator%2520of%2520Prenatal%2520Psychosocial%2520Distress%2520and%2520Birth%2520Outcomes%2520in%2520the%2520Healthy%2520Start%2520Cohort "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.26.26358958v1%26t%3DEvaluating%2520Allopregnanolone%2520as%2520a%2520Potential%2520Mediator%2520of%2520Prenatal%2520Psychosocial%2520Distress%2520and%2520Birth%2520Outcomes%2520in%2520the%2520Healthy%2520Start%2520Cohort "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.26.26358958v1%26title%3DEvaluating%2520Allopregnanolone%2520as%2520a%2520Potential%2520Mediator%2520of%2520Prenatal%2520Psychosocial%2520Distress%2520and%2520Birth%2520Outcomes%2520in%2520the%2520Healthy%2520Start%2520Cohort%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.07.26.26358958v1%26title%3DEvaluating%2520Allopregnanolone%2520as%2520a%2520Potential%2520Mediator%2520of%2520Prenatal%2520Psychosocial%2520Distress%2520and%2520Birth%2520Outcomes%2520in%2520the%2520Healthy%2520Start%2520Cohort "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.07.26.26358958v1&count=horizontal&via=&text=Evaluating%20Allopregnanolone%20as%20a%20Potential%20Mediator%20of%20Prenatal%20Psychosocial%20Distress%20and%20Birth%20Outcomes%20in%20the%20Healthy%20Start%20Cohort&counturl=www.medrxiv.org/content/10.64898/2026.07.26.26358958v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (592) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (884) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (321) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4665) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (465) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (400) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (629) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1584) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15610) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1171) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6860) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (709) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1031) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4834) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1409) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1689) * [Hematology](https://www.medrxiv.org/collection/hematology) (567) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1299) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16134) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1138) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (647) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (148) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (702) * [Neurology](https://www.medrxiv.org/collection/neurology) (6996) * [Nursing](https://www.medrxiv.org/collection/nursing) (357) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1054) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1205) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (985) * [Oncology](https://www.medrxiv.org/collection/oncology) (3495) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1011) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (381) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (431) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (453) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (135) * [Pathology](https://www.medrxiv.org/collection/pathology) (693) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1747) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (722) * [Prim
## Related Clinical Research

- [Metformin for Pain: Protocol for a Systematic Review of Safety and Efficacy](https://medichelpline.com/clinical-feed/bmj-open-12-safety-and-efficacy-of-metformin-for-the-treatment-of-pain-protocol-for-a.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [End-of-life symptom prevalence and drivers among hospital decedents in South Korea](https://medichelpline.com/clinical-feed/plos-one-3-prevalence-and-influencing-factors-of-end-of-life-symptoms-among-hospital.md)
- [Prevalence of cognitive impairment in older Palestinian adults in community and nursing homes](https://medichelpline.com/clinical-feed/plos-one-16-prevalence-of-cognitive-impairment-among-older-adult-palestinians-in-community.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.